Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Annals of surgical oncology

Dario Baratti, Shigeki Kusamura, Norfarizan Azmi, Marcello Guaglio, Matteo Montenovo, Marcello Deraco

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The Prodige-7 trial has questioned the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal metastases from colorectal cancer (CRC-PM). PATIENTS AND METHODS: We compared a prospectively collected group of 48 patients undergoing oxaliplatin/irinotecan-based perioperative systemic chemotherapy (s-CT) with targeted agents, and cytoreductive surgery (CRS) (no-HIPEC group) with 48 controls undergoing the same perioperative s-CT and CRS/HIPEC (HIPEC group). Patients were matched (1:1) according to the Peritoneal Surface Disease Severity Score, completeness of cytoreduction, history of extraperitoneal disease (EPD), and Peritoneal Cancer Index. RESULTS: The groups were comparable, except for a higher number of patients in the HIPEC group with World Health Organization performance status 0, pN2 stage primary tumor, and treated with preoperative s-CT. Forty-one patients in the no-HIPEC group and 43 patients in the HIPEC group had optimal comprehensive treatment (P = 0.759), defined as complete cytoreduction of PM and margin-negative EPD resection. Median follow-up was 31.6 months in the no-HIPEC group and 39.9 months in the HIPEC group. Median overall survival was 39.3 months in the no-HIPEC group and 34.8 months in the HIPEC group (P = 0.702). In the two groups, severe morbidity occurred in 14 (29.2%) and 13 (27.1%) patients, respectively (P = 1.000), with no operative deaths. On multivariate analysis, left-sided primary and curative treatment independently correlated with better survival while HIPEC did not (hazard ratio 0.73; 95% confidence interval 0.47-1.15; P = 0.178). CONCLUSIONS: Our results confirmed that, in selected patients, perioperative s-CT and surgical treatment of CRC-PM resulted in unexpectedly high survival rates. Mitomycin C-based HIPEC did not increase morbidity but did not impact prognosis.
Original languageEnglish
Pages (from-to)98-106
Number of pages9
JournalAnnals of Surgical Oncology
Volume27
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Combined Modality Therapy
  • Follow-Up Studies
  • Survival Rate
  • Lymphatic Metastasis
  • Prognosis
  • Case-Control Studies
  • Severity of Illness Index
  • Chemotherapy, Adjuvant
  • Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
  • Oxaliplatin/administration & dosage
  • Chemotherapy, Cancer, Regional Perfusion/*mortality
  • Colorectal Neoplasms/pathology/*therapy
  • Cytoreduction Surgical Procedures/*mortality
  • Hyperthermia, Induced/*mortality
  • Irinotecan/administration & dosage
  • Mitomycin/administration & dosage
  • Neoplasm Recurrence, Local/pathology/*therapy
  • Peritoneal Neoplasms/secondary/*therapy

Fingerprint Dive into the research topics of 'Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Annals of surgical oncology'. Together they form a unique fingerprint.

Cite this